摘要
我国目前心力衰竭(HF)的患病率仍高居不下,且其死亡率、再入院率无下降趋势,因此,对于其发生发展的作用机制亟待探讨。近年研究发现,约有13%~15%的HF患者合并亚临床甲状腺功能减退(SCH),后者可以导致心脏收缩、舒张功能障碍,从而促进HF的发生发展,目前临床上对于HF合并SCH患者中促甲状腺激素(TSH)水平轻度升高的患者其治疗疗效尚不明确,仍需要大量的前瞻性、多中心的研究数据进一步证实。此外,在HF的合并症中,SCH是唯一经过治疗后可逆转心脏功能的疾病,因此,本文对于SCH在HF发生发展过程中的作用机制进行归纳、总结,为其在临床HF治疗策略的制订及预后的评估提供依据。
At present,the prevalence of heart failure(HF)is still high in China,and its mortality and readmission rate have no downward trend.Therefore,the mechanism of its occurrence and development needs to be explored.In recent years,it has been found that about 13%-15%of HF patients have subclinical hypothyroidism(SCH),which can lead to cardiac systolic and diastolic dysfunction,thus promoting the occurrence and development of HF.At present,the curative effect of patients with mild elevation of thyroid stimulating hormone(TSH)level in HF patients with SCH is not clear,and a large number of prospective studies are still needed.In addition,in the complications of HF,SCH is the only disease that can reverse cardiac function after treatment.Therefore,this paper summarizes the mechanism of SCH in the occurrence and development of HF,and provides the basis for the formulation of clinical HF treatment strategies and the evaluation of prognosis.
作者
何晓雯
郭莹
He Xiaowen;Guo Ying(Department of Cardiology,the First Affiliated Hospital of Hunan Normal University,Hunan Provincial People′s Hospital,Changsha 410005,China)
出处
《中国医师杂志》
CAS
2021年第5期793-797,共5页
Journal of Chinese Physician
